Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
about
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directionsChanging paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patientsComparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxelPretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.Current management of prostate cancer: dilemmas and trialsThe unfolding treatment landscape for men with castration-resistant prostate cancer.The utility of prostate-specific antigen in the management of advanced prostate cancer.Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.Dihydrotestosterone synthesis pathways from inactive androgen 5α-androstane-3β,17β-diol in prostate cancer cells: Inhibition of intratumoural 3β-hydroxysteroid dehydrogenase activities by abiraterone.Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles.Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
P2860
Q34324736-82300EF2-8521-452A-B222-9D428CEBD2B0Q35213324-B0753D48-BBED-4899-928C-FCA564C6165BQ35602593-DC64A859-6FA2-4F6A-AD38-E5A2366DC7FCQ36416408-EB078821-85CF-407C-9CD1-BD48E4B485AAQ36483161-41F2D0FA-DEDD-4995-9E0F-836A7652BCC6Q37102535-49920A4D-83DA-432C-8CA2-60E42BBE4EB3Q38056914-16182EEA-AF26-464B-9F4A-144BE18DA1CDQ38119260-F4A16556-BBA0-4DF6-8523-78C3888DEABEQ38221851-9A3EAD04-5AA4-4293-BF40-67128EF241E3Q41108522-C5553FCC-1AEE-4837-8AF3-30E2DDCC252EQ49387572-5952D991-B043-4343-88E2-61D2F7C230C1Q53176477-4B0D052E-D1DF-4F8C-A47E-C66A7B28FFE4
P2860
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Contemporary experience with k ...... ponse and disease progression.
@ast
Contemporary experience with k ...... ponse and disease progression.
@en
type
label
Contemporary experience with k ...... ponse and disease progression.
@ast
Contemporary experience with k ...... ponse and disease progression.
@en
prefLabel
Contemporary experience with k ...... ponse and disease progression.
@ast
Contemporary experience with k ...... ponse and disease progression.
@en
P2093
P2860
P356
P1433
P1476
Contemporary experience with k ...... ponse and disease progression.
@en
P2093
Daniel Keizman
Mario A Eisenberger
Michael A Carducci
Peng Huang
P2860
P304
P356
10.1002/PROS.21447
P577
2011-06-17T00:00:00Z